ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37 th Annual Healthcare Conference on Wednesday, December 3, 2025 . Event: Piper Sandler 37 th Annual Healthcare Conference Date: Wednesday, December 3, 2025 Time: 8:00am ET/5:00am PT A webcast of the presentation can be accessed on the "Events and Presentations"... Read More

ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025 . Revenue of $354.7 million in the third quarter of 2025, an increase of 17.8% or 16.9% in constant currency 1 , compared to the third quarter of 2024. Total U.S. revenue of $275.0 million in the third quarter of 2025, an increase... Read More

The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation Results of STORM-PE demonstrating superior efficacy of CAVT with anticoagulation versus anticoagulation alone... Read More

ALAMEDA, Calif. , Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high... Read More

ALAMEDA, Calif. , Oct. 8, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference. Management and members of the STORM-PE steering committee will discuss the Company's STORM-PE clinical trial followed by a question-and-answer... Read More

Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif. , Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE: PEN), The PERT Consortium® and Society for Vascular Medicine (SVM), which have come together to... Read More

ALAMEDA, Calif. , Aug. 27, 2025 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025 . She will continue to report to Adam Elsesser , who served in the role of President prior to this promotion and will continue in his roles as chairman of the board and chief executive officer of... Read More

ALAMEDA, Calif. , Aug. 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Time: 8:45am ET/5:45am PT Event: Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Tuesday, September 9, 2025 Time:... Read More

ALAMEDA, Calif. , July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45 th Annual Growth Conference on Tuesday, August 12, 2025 . Event: Canaccord Genuity 45 th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 12:30pm ET/9:30am PT A webcast of the presentation can be accessed on the "Events and Presentations" section... Read More

ALAMEDA, Calif. , July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025 . Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency 1 , compared to the second quarter of 2024. U.S. Thrombectomy revenue of $188 .5 million in the second quarter of 2025, an... Read More

ALAMEDA, Calif. , July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time . A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be... Read More

STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif. , June 16, 2025 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE... Read More

ALAMEDA, Calif. , June 5, 2025 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby ® XL System, the longest, largest and softest coil on the market i . The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow... Read More

ALAMEDA, Calif. , May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event: William Blair 45 th Annual Growth Stock Conference Date: Tuesday, June 3, 2025 Time: 3:00pm ET/12:00pm PT Event: Jefferies Global Healthcare Conference Date: Wednesday, June 4, 2025 Time: 9:55am ET/6:55am PT... Read More

ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 . Event: BofA Securities 2025 Health Care Conference Date: Tuesday, May 13, 2025 Time: 6:00pm ET / 3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the... Read More

ALAMEDA, Calif. , April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025 . Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency 1 , compared to the first quarter of 2024. U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an... Read More

ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time . A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be... Read More

ALAMEDA, Calif. , April 2, 2025 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also... Read More

ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025 . Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015. "We are grateful for Don's many... Read More

ALAMEDA, Calif. , Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024 . Financial Highlights: Adjusted revenue 1 of $321.3 million , excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted 2 or 13.0% in... Read More

ALAMEDA, Calif. , Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time . A press release with fourth quarter and full year 2024 financial results will be issued after market close that day. Webcast & Conference Call Information... Read More

ALAMEDA, Calif. , Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 . Event: 43 rd Annual J.P. Morgan Healthcare Conference Date: Monday, January 13, 2025 Time: 6:00pm ET / 3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section... Read More

ALAMEDA, Calif. , Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36 th Annual Healthcare Conference on Wednesday, December 4, 2024 . Event: Piper Sandler 36 th Annual Healthcare Conference Date: Wednesday, December 4, 2024 Time: 8:00am ET / 5:00am PT A webcast of the presentation can be accessed on the "Events and Presentations"... Read More

Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif. , Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with... Read More

ALAMEDA, Calif. , Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024 . Revenue of $301.0 million in the third quarter of 2024, an increase of 11.1% or 10.9% in constant currency 1 , compared to the third quarter of 2023. U.S. thrombectomy revenue of $162.1 million in the third quarter of 2024... Read More

ALAMEDA, Calif. , Oct. 14, 2024 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company's latest computer assisted vacuum thrombectomy (CAVT™) technology, Penumbra System™ with Thunderbolt™ Aspiration Tubing, for the removal... Read More

ALAMEDA, Calif. , Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time . A press release with third quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be... Read More

Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus... Read More

ALAMEDA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024 . Event: Baird Global Healthcare Conference Date: Tuesday, September 10, 2024 Time: 9:05am ET / 6:05am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors"... Read More

ALAMEDA, Calif. , Aug. 21, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 . Event: Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 2:15pm ET/11:15am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors"... Read More

To Include $100 Million Accelerated Share Repurchase ALAMEDA, Calif. , Aug. 13, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share repurchase authorization in the amount of up to $200 million , allowing Penumbra to repurchase its common stock from time to time at such prices as it deems appropriate through... Read More

ALAMEDA, Calif. , Aug. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Growth Conference on Tuesday, August 13, 2024 . Event: Canaccord Genuity Growth Conference Date: Tuesday, August 13, 2024 Time: 9:00am ET/ 6:00am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab... Read More

ALAMEDA, Calif. , July 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024 . Revenue of $299.4 million in the second quarter of 2024, an increase of 14.5% or 14.7% in constant currency 1 , compared to the second quarter of 2023. U.S. thrombectomy revenue of $153.7 million in the second... Read More

ALAMEDA, Calif. , July 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2024 after market close on Tuesday, July 30, 2024 at 4:30 PM Eastern Time . A press release with second quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be... Read More

ALAMEDA, Calif. , June 4, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 . Event: Truist Securities MedTech Conference Date: Tuesday, June 18, 2024 Time: 10:05am ET/7:05am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of... Read More

ALAMEDA, Calif. , May 23, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair Growth Stock Conference on Thursday, June 6, 2024 . Event: William Blair Growth Stock Conference Date: Thursday, June 6, 2024 Time: 12:20pm ET/9:20am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab... Read More

ALAMEDA, Calif. , May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024 . Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency 1 , compared to the first quarter of 2023. U.S. thrombectomy revenue of $150.3 million in the first quarter... Read More

ALAMEDA, Calif. , May 1, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024 . Event: RBC Capital Markets Global Healthcare Conference Date: Wednesday, May 15, 2024 Time: 8:00am ET/5:00am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under... Read More

Lightning Flash™ 2.0 features advanced computer assisted vacuum thrombectomy (CAVT) software, designed for increased efficiency and sensitivity to enhance removal of venous thrombus and treatment of pulmonary emboli (PE) Combined with streamlined audio-visual feedback, Lightning Flash 2.0 is designed to enable physicians to... Read More

ALAMEDA, Calif. , April 9, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time . A press release with first quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be accessed... Read More

ALAMEDA, Calif. , Feb. 22, 2024 /PRNewswire/ -- Penumbra, Inc. ( NYSE: PEN ) , a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023 . Financial Highlights: Revenue of $284.7 million for the fourth quarter of 2023, an increase of 28.7% or 27.9% in constant currency 1 compared to the fourth quarter of 2022. Revenue of $1,058.5... Read More

ALAMEDA, Calif. , Feb. 1, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024 at 4:30 PM Eastern Time . A press release with fourth quarter and full year 2023 financial results will be issued after market close that day. Webcast & Conference Call Information... Read More

ALAMEDA, Calif. , Dec. 18, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on Monday, January 8, 2024 . Event: J.P. Morgan 42nd Annual Healthcare Conference Date: Monday, January 8, 2024 Time: 11:15am ET / 8:15am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under... Read More

First-of-its-kind randomized controlled trial comparing computer assisted vacuum thrombectomy (CAVT) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone Penumbra's Indigo ® Aspiration with Lightning portfolio offers the only CAVT technologies currently available in the U.S. and Lightning Flash... Read More

ALAMEDA, Calif. , Nov. 14, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28, 2023 . Event: Piper Sandler 35 th Annual Healthcare Conference Date: Tuesday, November 28, 2023 Time: 1:30pm ET/10:30am PT A webcast of the presentation can be accessed on the "Events and Presentations"... Read More

ALAMEDA, Calif. , Nov. 10, 2023 /PRNewswire/ -- Everyday, memories of the people who served in World War II, Vietnam , and the Korean War are disappearing from living history. Virtual reality companies from around the world have teamed up in a program called "Honor Everywhere" to ensure the memorials are still accessible to... Read More

ALAMEDA, Calif. , Nov. 2, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2023 . Revenue of $270.9 million in the third quarter of 2023, an increase of 26.8% or 25.9% in constant currency 1 , compared to the third quarter of 2022 . Revenue of $179.1 million from sales of our thrombectomy... Read More

Latest STRIKE-PE data show that computer assisted vacuum thrombectomy (CAVT) for the treatment of pulmonary embolism is safe and effective at reducing right heart strain; it also improved clinical and functional outcomes Penumbra's Indigo ® Aspiration with Lightning™ portfolio offers the only CAVT technologies currently available in the U.S. ALAMEDA, Calif. , Nov. 1, 2023 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), a global... Read More

ALAMEDA, Calif. , Oct. 5, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2023 after market close on Thursday, November 2, 2023 at 4:30 PM Eastern Time. A press release with third quarter 2023 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be... Read More

ALAMEDA, Calif. , Aug. 23, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below: Event: 2023 Wells Fargo Healthcare Conference Date: Wednesday, September 6, 2023 Time: 8:00am ET/5:00am PT Event: Baird 2023 Global Healthcare Conference Date: Tuesday, September 12, 2023 Time: 2:00pm ET/11:00am... Read More

ALAMEDA, Calif. , Aug. 1, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2023 . Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as reported and in constant currency 1 compared to the second quarter of 2022. Second Quarter 2023 Financial Results Total revenue... Read More

ALAMEDA, Calif. , July 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 . Event: Canaccord Genuity 43rd Annual Growth Conference Date: Wednesday, August 9, 2023 Time: 9:00am ET/ 6:00am PT A webcast of the presentation will be available by visiting the investors' section of... Read More

ALAMEDA, Calif. , July 5, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2023 after market close on Tuesday, August 1, 2023 at 4:30 PM Eastern Time . A press release with second quarter 2023 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be... Read More

Lightning Bolt™ 7 is the most advanced arterial thrombectomy system on the market Latest technology combines modulated aspiration with superior catheter design to maximize blood clot removal in a single session ALAMEDA, Calif. , June 1, 2023 /PRNewswire/ -- Penumbra, In c . (NYSE: PEN), a global healthcare company focused on... Read More

ALAMEDA, Calif. , May 24, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at William Blair's 43 rd Annual Growth Stock Conference on Wednesday, June 7, 2023 . Event: William Blair's 43 rd Annual Growth Stock Conference Date: Wednesday, June 7, 2023 Time: 9:20am CT/ 7:20am PT A webcast of the presentation will be available by visiting the investors' section of... Read More

Revenue of $241.4 million in the first quarter of 2023, an increase of 18.4%, or 19.7% in constant currency 1 , compared to the first quarter of 2022. ALAMEDA, Calif. , May 2, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2023 . First Quarter 2023 Financial Results Total revenue increased to... Read More

ALAMEDA, Calif. , April 25, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below: Event: Bank of America Securities 2023 Health Care Conference Date: Tuesday, May 9, 2023 Time: 1:40pm ET / 10:40am PT Event: 2023 RBC Capital Markets Global Healthcare Conference Date: Tuesday, May 16, 2023 Time:... Read More

ALAMEDA, Calif. , April 4, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023 at 4:30 PM Eastern Time . A press release with first quarter 2023 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be accessed... Read More

Penumbra enters a three-year collaboration with VHA Office of Healthcare Innovation and Learning to test, co-develop and scale virtual reality solutions Collaboration to develop and implement therapy software and programs on Penumbra's REAL y-Series platform to address critical veterans' needs, including remote therapeutic... Read More

Lightning Flash™ is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus Next generation technology combines superior catheter design with the latest dual clot detection innovation ALAMEDA, Calif. , Jan. 10, 2023 /PRNewswire/ -- Penumbra, Inc . (NYSE: PEN), a global healthcare... Read More

ALAMEDA, Calif. , Dec. 19, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 . Event: 41 st Annual J.P. Morgan Healthcare Conference Date: Monday, January 9, 2023 Time: 1:30pm ET / 10:30am PT A webcast of the presentation will be available by visiting the investors' section of the... Read More